Protein / target
Sodium-dependent dopamine transporter
Protein at a glance
Biological role
Neurotransmitter transmembrane transporter activity
Primary system
Nervous system
Strongest disease association
classic dopamine transporter deficiency syndrome
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
28 approved · 10 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)
Subcellular location
Domains and Gene Ontology detail (38)Hide
Gene Ontology
- Caxon
- Caxon terminus
- Ccell surface
- Ccytoplasm
- Cdopaminergic synapse
- Cflotillin complex
- Cmembrane
- Cmembrane raft
- Cneuron projection
- Cneuronal cell body
- Cplasma membrane
- Cpostsynaptic membrane
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·dopaminergic synapse
- ·postsynaptic membrane
- ·presynaptic membrane
- ·dopamine uptake involved in synaptic transmission
Ion channel gating
- ·sodium ion transmembrane transport
Proteolysis
- ·protease binding
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Dopamine transporter releasing agent
Appears in clinical studies involving attention deficit-hyperactivity disorder, attention deficit-hyperactivity disorder, attention deficit-hyperactivity disorder, cocaine dependence
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,307 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 41 total
attention deficit-hyperactivity disorder · Huntington disease · binge eating disorder
major depressive disorder · breast cancer
Overweight · Obesity · major depressive disorder
major depressive disorder · major depressive disorder · treatment resistant depression
Obesity
attention deficit-hyperactivity disorder · Pain · obsessive-compulsive disorder
attention deficit-hyperactivity disorder · narcolepsy-cataplexy syndrome · Hyperactivity
Pain · Dyskinesia · Parkinson disease
obesity disorder
attention deficit-hyperactivity disorder · eating disorder · mood disorder
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (4)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- New publicationAstroglial CB<sub>1</sub> Reveal Sex-Specific Synaptic Effects of Amphetamine.
- New publicationAstrocytes Mediate Psychostimulant-Induced Alterations of Spike-Timing Dependent Synaptic Plasticity.
- New publicationComparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.
- New publicationAnimal models of schizophrenia.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.